These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8406387)

  • 41. Histochemical demonstration of sugar residues by lectin and immunocytochemical techniques for blood group antigens in human colon.
    Nakayama J; Ota M; Honda T; Katsuyama T
    Histochem J; 1987 Aug; 19(8):454-64. PubMed ID: 3429260
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mucin histochemistry and lectin binding sites in intestinal metaplasia of the urinary bladder.
    Barresi G; Marafioti T
    Histopathology; 1990 Sep; 17(3):219-23. PubMed ID: 2242849
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Peanut lectin binding in breast carcinoma. Lack of correlation with estrogen receptor content.
    Stanley MW; Kiang DT; Sibley RK
    Cancer; 1986 Nov; 58(9):2046-51. PubMed ID: 2428465
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The distribution of ABO(H) isoantigens in urinary bladder tumours.
    Baranyay F; Knels R; Somogyi L
    Acta Med Hung; 1992-1993; 49(1-2):129-36. PubMed ID: 1296182
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunoperoxidase detection of carcinoembryonic antigen and blood group substances in papillary transitional cell carcinoma of the bladder.
    Wiley EL; Mendelsohn G; Droller MJ; Eggleston JC
    J Urol; 1982 Aug; 128(2):276-80. PubMed ID: 7050419
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Expression of A,B and H blood group antigens in urothelial carcinoma of the urinary bladder].
    Tichý M; Tichá V; Jansa P; Student V; Vanák J
    Cesk Patol; 1991 Mar; 27(1-2):13-9. PubMed ID: 1893425
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peanut lectin-binding sites in polyps of the colon and rectum. Adenomas, hyperplastic polyps, and adenomas with in situ carcinoma.
    Cooper HS; Reuter VE
    Lab Invest; 1983 Dec; 49(6):655-61. PubMed ID: 6656197
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The relationship of ABH(O) blood group antigen expression in intraepithelial dysplastic lesions to clinicopathologic properties of associated transitional cell carcinoma of the bladder.
    Yamada T; Fukui I; Kobayashi T; Sekine H; Yokogawa M; Yamada T; Oshima H
    Cancer; 1991 Mar; 67(6):1661-6. PubMed ID: 2001555
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blood group antigens and bladder carcinoma: a perspective.
    Stein BS; Kendall AR
    Urology; 1982 Sep; 20(3):229-33. PubMed ID: 7123712
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monoclonal antibodies against transitional cell carcinoma for detection of malignant urothelial cells in bladder washing.
    Chopin DK; deKernion JB; Rosenthal DL; Fahey JL
    J Urol; 1985 Aug; 134(2):260-5. PubMed ID: 3894692
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Correlations between grading and presence of blood group isoantigens in papillary urothelial-cell carcinoma of the bladder with low grade malignancy].
    Mattarozzi A; Zanella L; Bacchini P; Bertoni F; Ferramosca B
    Pathologica; 1985; 77(1050):395-400. PubMed ID: 3834371
    [No Abstract]   [Full Text] [Related]  

  • 52. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
    Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
    J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Coexistence of papillary and nodular carcinomas in the urinary bladder.
    Kakizoe T; Matsumoto K; Tobisu K; Takai K; Teshima S; Kishi K
    Jpn J Clin Oncol; 1987 Jun; 17(2):179-86. PubMed ID: 3613141
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
    Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
    J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognosis of transitional cell bladder carcinoma. With special reference to ABH blood group isoantigen expression and DNA analysis.
    Malmström PU
    Scand J Urol Nephrol Suppl; 1988; 112():1-55. PubMed ID: 3068792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ.
    Althausen AF; Prout GR; Daly JJ
    J Urol; 1976 Nov; 116(5):575-80. PubMed ID: 978809
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blood group antigens in urothelium in transitional cell carcinoma.
    Giraldo AA; Ruby SG; Humes JJ
    Ann Clin Lab Sci; 1983; 13(4):307-14. PubMed ID: 6354063
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Urinary cytology in the detection of bladder tumours. Influence of concomitant urothelial atypia.
    Harving N; Petersen SE; Melsen F; Wolf H
    Scand J Urol Nephrol Suppl; 1989; 125():127-31. PubMed ID: 2633311
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Superficial tumor of the bladder with associated carcinoma in situ: new occurrences and increase of tumor stage].
    Ojea Calvo A; Nogueira March JL; Figueiredo L; Jamardo D; Benavente J; Castro M
    Actas Urol Esp; 1991; 15(2):139-42. PubMed ID: 1807107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blood group isoantigen deletion in carcinoma in situ of the urinary bladder.
    Weinstein RS; Alroy J; Farrow GM; Miller AW; Davidsohn I
    Cancer; 1979 Feb; 43(2):661-8. PubMed ID: 421187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.